Zealand Pharma A/S
CSE:ZEAL
Intrinsic Value
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design and development of peptide based medicines. [ Read More ]
The intrinsic value of one ZEAL stock under the Base Case scenario is 305.63 DKK. Compared to the current market price of 657.5 DKK, Zealand Pharma A/S is Overvalued by 54%.
Valuation Backtest
Zealand Pharma A/S
Run backtest to discover the historical profit from buying and selling ZEAL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Zealand Pharma A/S
Current Assets | 1.8B |
Cash & Short-Term Investments | 1.6B |
Receivables | 110.8m |
Other Current Assets | 35.9m |
Non-Current Assets | 200.2m |
Long-Term Investments | 21.4m |
PP&E | 149.9m |
Intangibles | 12.3m |
Other Non-Current Assets | 16.7m |
Current Liabilities | 284.6m |
Accounts Payable | 206.1m |
Accrued Liabilities | 51.7m |
Other Current Liabilities | 26.7m |
Non-Current Liabilities | 102.6m |
Long-Term Debt | 102.6m |
Earnings Waterfall
Zealand Pharma A/S
Revenue
|
342.8m
DKK
|
Cost of Revenue
|
-19.2m
DKK
|
Gross Profit
|
323.6m
DKK
|
Operating Expenses
|
-884.9m
DKK
|
Operating Income
|
-561.2m
DKK
|
Other Expenses
|
-142.5m
DKK
|
Net Income
|
-703.7m
DKK
|
Free Cash Flow Analysis
Zealand Pharma A/S
ZEAL Profitability Score
Profitability Due Diligence
Zealand Pharma A/S's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Zealand Pharma A/S's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
ZEAL Solvency Score
Solvency Due Diligence
Zealand Pharma A/S's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Zealand Pharma A/S's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZEAL Price Targets Summary
Zealand Pharma A/S
According to Wall Street analysts, the average 1-year price target for ZEAL is 805.04 DKK with a low forecast of 606 DKK and a high forecast of 882 DKK.
Shareholder Return
ZEAL Price
Zealand Pharma A/S
Average Annual Return | 17.32% |
Standard Deviation of Annual Returns | 45.21% |
Max Drawdown | -76% |
Market Capitalization | 38.4B DKK |
Shares Outstanding | 62 270 400 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design and development of peptide based medicines. The firm's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.
Contact
IPO
Employees
Officers
The intrinsic value of one ZEAL stock under the Base Case scenario is 305.63 DKK.
Compared to the current market price of 657.5 DKK, Zealand Pharma A/S is Overvalued by 54%.